Meeting
2011 ASCO Annual Meeting
Survival after brain metastases in Asian patients with HER2+ breast cancer.
Authors
Y. S. Yap
National Cancer Centre, Singapore, Singapore
Y. S. Yap , B. C. Devi , C. Khorprasert , G. H. Cornelio , N. Sutandyo , E. Yeoh , S. Landis , M. Kobayashi , H. Moon , J. Ro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 29: 2011 (suppl; abstr 543)
Abstract #
543
Poster Bd #
1G
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Response to ado-trastuzumab emtansine according to RANO criteria in central nervous system metastases of HER2 positive breast cancers.
First Author: Audrey Mailliez
Poster
2021 ASCO Annual Meeting
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
First Author: Erica Michelle Stringer-Reasor
Poster
2019 ASCO Annual Meeting
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.
First Author: Zachary William Neil Veitch
Poster
2018 ASCO Annual Meeting
Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.
First Author: Zongbi Yi